<br>卡那奴单抗治疗对家族性地中海热患儿生长参数的影响,Clinical Rheumatology

当前位置： X-MOL 学术 › Clin. Rheumatol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

卡那奴单抗治疗对家族性地中海热患儿生长参数的影响
Clinical Rheumatology ( IF 2.9 ) Pub Date : 2023-09-02 , DOI: 10.1007/s10067-023-06752-z
Elif Arslanoglu Aydin ₁ , Esra Baglan ₁ , Nesibe Gokce Kocamaz ₁ , İlknur Bagrul ₁ , Serife Tuncez ₁ , Semanur Ozdel ₁

Affiliation

简介/目标

本研究旨在评估卡那奴单抗对家族性地中海热（FMF）儿童生长参数的影响。

方法

我们对我们中心随访的 946 名儿童 FMF 患者进行了回顾性分析，其中 37 名患者接受了至少三剂卡那奴单抗治疗。对患者的人口统计学、临床和遗传特征进行评估。记录卡那奴单抗治疗前后的身高和体重百分位数以及Z评分数据并进行比较。

结果

研究组由 37 名接受卡那奴单抗治疗的 FMF 患者组成。诊断时和卡那单抗开始时的中位年龄 (IQR) 分别为 3.0 (2.0-4.3) 岁和 7.0 (3.6-10.1) 岁。卡那单抗治疗后，中位体重评分和平均体重指数 (BMI) 值显着增加。卡那单抗治疗后身高评分没有变化。

结论

卡那奴单抗治疗通过控制疾病活动和炎症改善了 FMF 患者的体重和 BMI 参数。

关键点

•据我们所知，文献中很少有研究评估卡那奴单抗治疗FMF 儿童的生长参数。

•卡那奴单抗治疗已被证明可以对体重和体重指数产生积极影响。

•需要对其对身高的影响进行长期研究。

"点击查看英文标题和摘要"

The effect of canakinumab treatment on growth parameters in children with familial Mediterranean fever

Introduction/objectives

This study aimed to evaluate the effect of canakinumab on growth parameters in children with familial Mediterranean fever (FMF).

Method

We conducted a retrospective analysis of 946 pediatric FMF patients followed in our center, of whom 37 were treated with canakinumab for at least three doses. Patients were assessed for demographic, clinical, and genetic characteristics. Data of height and weight percentiles and Z scores were recorded before and after canakinumab treatment and compared.

Results

The study group comprised 37 FMF patients with treated canakinumab. The median age (IQR) at diagnosis and canakinumab initiation was 3.0 (2.0–4.3) years and 7.0 (3.6–10.1) years, respectively. The median weight scores and mean body mass index (BMI) values significantly increased after canakinumab treatment. There was no change in height scores following canakinumab treatment.